116 related articles for article (PubMed ID: 33417323)
1. Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy.
Parikh AB; Zhong X; Mellgard G; Qin Q; Patel VG; Wang B; Alerasool P; Garcia P; Leiter A; Gallagher EJ; Clinton S; Mortazavi A; Monk P; Folefac E; Yin M; Yang Y; Galsky M; Oh WK; Tsao CK
Am J Clin Oncol; 2021 Mar; 44(3):114-120. PubMed ID: 33417323
[TBL] [Abstract][Full Text] [Related]
2. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
3. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
[No Abstract] [Full Text] [Related]
4. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors.
Guven DC; Sahin TK; Aksun MS; Taban H; Aktepe OH; Aksu NM; Akkaş M; Erman M; Kilickap S; Dizdar O; Aksoy S
Support Care Cancer; 2021 Apr; 29(4):2029-2035. PubMed ID: 32851486
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
9. The role of income in reducing racial and ethnic disparities in emergency room and urgent care center visits for asthma-United States, 2001-2009.
Law HZ; Oraka E; Mannino DM
J Asthma; 2011 May; 48(4):405-13. PubMed ID: 21504353
[TBL] [Abstract][Full Text] [Related]
10. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Kostine M; Mauric E; Tison A; Barnetche T; Barre A; Nikolski M; Rouxel L; Dutriaux C; Dousset L; Prey S; Beylot-Barry M; Seneschal J; Veillon R; Vergnenegre C; Daste A; Domblides C; Sionneau B; Gross-Goupil M; Ravaud A; Forcade E; Schaeverbeke T;
Eur J Cancer; 2021 Nov; 157():474-484. PubMed ID: 34649118
[TBL] [Abstract][Full Text] [Related]
11. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
12. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
[TBL] [Abstract][Full Text] [Related]
13. Electronic medical record analysis of emergency room visits and hospitalizations in individuals with epilepsy and mental illness comorbidity.
Sajatovic M; Welter E; Tatsuoka C; Perzynski AT; Einstadter D
Epilepsy Behav; 2015 Sep; 50():55-60. PubMed ID: 26119621
[TBL] [Abstract][Full Text] [Related]
14. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
Zhang L; Bai L; Liu X; Liu Y; Li S; Liu J; Zhang S; Yang C; Ren X; Cheng Y
Thorac Cancer; 2020 May; 11(5):1170-1179. PubMed ID: 32134200
[TBL] [Abstract][Full Text] [Related]
15. Inpatient and emergency room visits for adolescents and young adults with spina bifida living in South Carolina.
Mann JR; Royer JA; Turk MA; McDermott S; Holland MM; Ozturk OD; Hardin JW; Thibadeau JK
PM R; 2015 May; 7(5):499-511. PubMed ID: 25511690
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy.
Kanjanapan Y; Yip D
Cancer Med; 2020 Dec; 9(23):9027-9035. PubMed ID: 33159505
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
Durbin SM; Zubiri L; Niemierko A; Bardia A; Sullivan RJ; McEwen C; Mulvey TM; Allen IM; Lawrence DP; Cohen JV; Hochberg EP; Ryan DP; Petrillo LA; Reynolds KL
Oncologist; 2021 Jan; 26(1):49-55. PubMed ID: 33044765
[TBL] [Abstract][Full Text] [Related]
19. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
